Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that its controlled subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has received Breakthrough Therapy Drug (BTD) designation from China’s Center for Drug Evaluation (CDE) for ZSP1601 Tablets, a first‑in‑class (FIC) innovative drug with a novel mechanism of action for the treatment of metabolic associated steatohepatitis (MASH). The designation, formally listed on the Breakthrough Therapy Drug Catalog as of 29 September 2026, is backed by positive Phase IIb clinical data demonstrating histological improvement at 48 weeks and grants ZSP1601 priority regulatory resources and enhanced guidance from the CDE.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | Center for Drug Evaluation (CDE), NMPA |
| Designation Type | Breakthrough Therapy Drug (BTD) Program |
| Receipt Number | CXHL1600223 |
| Product | ZSP1601 Tablets |
| Drug Classification | Chemical drug, Class 1 (innovative) |
| Indication | Metabolic Associated Steatohepatitis (MASH) |
| Designation Date | 29 September 2026 (formal listing) |
| Regulatory Basis | Measures for Drug Registration Administration and CDE Breakthrough Therapy Drug Review Procedures (Trial) (Announcement No. 82, 2020) |
| Regulatory Benefit | Priority resource allocation, enhanced regulatory communication, and accelerated development guidance from CDE |
Drug Profile & Mechanism of Action
- Molecule: ZSP1601, a first‑in‑class (FIC) small‑molecule chemical drug with a novel, proprietary mechanism of action for MASH treatment.
- Intellectual Property: Global proprietary IP rights — independently developed by Zhongsheng Ruichuang.
- Strategic Importance: Designated as a National Major New Drug Creation Project (国家重大新药创制项目), reflecting its strategic significance in China’s pharmaceutical innovation agenda.
- Development Stage: Phase IIb completed with positive results; positioned for pivotal Phase III trials under BTD accelerated pathway.
Clinical Evidence – Phase IIb Trial
- Primary Endpoint Met: ZSP1601 achieved the primary efficacy endpoint of histological improvement after 48 weeks of treatment in the Phase IIb clinical trial.
- Triple Benefit Observed:
- Anti‑fibrosis — demonstrated efficacy in reducing liver fibrosis
- Hepatic fat reduction — significant decrease in liver fat content
- Liver enzyme improvement — favorable changes in hepatic biomarkers
- Clinical Profile: Characterized by rapid onset of action, robust efficacy, and excellent safety and tolerability.
- Detailed Data: Specific numerical results (e.g., responder rates, fibrosis stage improvement, ALT/AST changes) were not disclosed in this announcement; refer to the company’s prior disclosure dated 8 May 2026 for additional detail.
Market Impact & Outlook
- MASH – A High‑Value Unmet Need: Metabolic associated steatohepatitis (formerly NASH) is one of the largest underserved therapeutic areas in hepatology, with an estimated global prevalence of ~5% and rising incidence driven by obesity and metabolic syndrome epidemics. No pharmacotherapy is currently approved in China for MASH, creating a substantial addressable market.
- First‑in‑Class Differentiation: ZSP1601’s novel mechanism of action positions it outside the crowded landscape of FXR agonists, THR‑β agonists, and PPAR modulators, potentially offering a differentiated efficacy and safety profile that could expand the treatable patient population.
- Triple‑Endpoint Achievement: The simultaneous demonstration of anti‑fibrotic, steatotic, and biochemical benefits at 48 weeks is a meaningful signal, as regulatory agencies (including the U.S. FDA and EMA) have increasingly emphasized histological endpoints — particularly fibrosis resolution without worsening of steatohepatitis — as the basis for accelerated and full approvals.
- BTD Acceleration: The Breakthrough Therapy Drug designation provides ZSP1601 with priority CDE engagement, potentially shortening the development‑to‑approval timeline through enhanced regulatory dialogue and expedited review procedures.
- National Strategic Backing: As a National Major New Drug Creation Project, ZSP1601 benefits from government‑level policy support and visibility, reinforcing its strategic value within Zhongsheng’s innovation portfolio.
- Platform and Pipeline Implications: Success of ZSP1601 would validate Zhongsheng Ruichuang’s drug discovery capabilities and could catalyze partnership or licensing interest from global pharmaceutical companies seeking MASH assets with differentiated mechanisms.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical development plans, and commercial expectations for ZSP1601. Actual results may differ materially due to risks including Phase III trial design and outcomes, regulatory review timelines, competitive developments in the MASH therapeutic space, manufacturing scale‑up, market access dynamics, and the inherent uncertainties of new drug development. Investors are advised to exercise caution.-Fineline Info & Tech
